News coverage about Zogenix (NASDAQ:ZGNX) has trended somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies negative and positive press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Zogenix earned a coverage optimism score of 0.08 on Accern’s scale. Accern also gave media coverage about the company an impact score of 45.3853539476929 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
These are some of the headlines that may have impacted Accern Sentiment’s scoring:
- Zogenix (ZGNX) Begins Phase 3 Trial for ZX008 in Lennox-Gastaut Syndrome (streetinsider.com)
- Zogenix Announces Initiation of Phase 3 Trial for ZX008 in Lennox-Gastaut Syndrome (finance.yahoo.com)
- Zogenix to Participate in the Global Mizuho Investor Conference 2017 (feeds.benzinga.com)
- Zogenix To Host Call with Pediatric Epilepsy Expert Joseph Sullivan, M.D., on Dravet Syndrome and ZX008 on Monday, December 4 (finance.yahoo.com)
- As Zogenix Develops Its Seizure Treatment Pipeline, Analyst Predicts More Upside (msn.com)
Several equities analysts have recently commented on the company. BidaskClub lowered Zogenix from a “hold” rating to a “sell” rating in a research note on Saturday, August 12th. ValuEngine lowered Zogenix from a “hold” rating to a “sell” rating in a research note on Saturday, August 12th. JMP Securities started coverage on Zogenix in a research note on Monday, November 27th. They issued an “outperform” rating and a $56.00 price target on the stock. Zacks Investment Research lowered Zogenix from a “hold” rating to a “sell” rating in a research note on Saturday, August 12th. Finally, Mizuho reissued a “buy” rating and set a $51.00 target price (up previously from $28.00) on shares of Zogenix in a research note on Friday, September 29th. Three investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $42.67.
Zogenix (ZGNX) opened at $38.90 on Friday. Zogenix has a 12 month low of $7.70 and a 12 month high of $42.60. The company has a quick ratio of 2.71, a current ratio of 2.71 and a debt-to-equity ratio of 0.23.
In other news, major shareholder Life Sciences Maste Perceptive bought 300,000 shares of the firm’s stock in a transaction that occurred on Tuesday, October 3rd. The shares were purchased at an average price of $37.50 per share, with a total value of $11,250,000.00. The transaction was disclosed in a filing with the SEC, which is available at this link. 5.00% of the stock is currently owned by corporate insiders.
TRADEMARK VIOLATION WARNING: “Zogenix (ZGNX) Given Coverage Optimism Score of 0.08” was published by Transcript Daily and is the sole property of of Transcript Daily. If you are viewing this report on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The legal version of this report can be accessed at https://transcriptdaily.com/2017/12/02/zogenix-zgnx-given-coverage-optimism-score-of-0-08.html.
Zogenix, Inc is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders. Its primary area of therapeutic focus is epilepsy and related seizure disorders. Its lead product candidate, ZX008, is a low-dose fenfluramine for the treatment of seizures associated with Dravet syndrome.
Receive News & Ratings for Zogenix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zogenix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.